Efficacy, Safety of Nivolumab Plus Cabozantinib Versus Sunitinib for Patients With Advanced Renal Cell Carcinoma

Video

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, discusses her presentation on nivolumab plus cabozantinib versus sunitinib for aRCC.

Pharmacy Times interviewed Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, on her presentation at the 2021 ASCO Annual Meeting on nivolumab plus cabozantinib versus sunitinib for advanced renal cell carcinoma (aRCC).

During the discussion, Apolo detailed some of the findings of the phase 3 trial around the efficacy and safety of nivolumab plus cabozantinib versus sunitinib for patients with aRCC.

Related Videos
Image credit:  Gorodenkoff | stock.adobe.com
Pharmacist and Patient in Pharmacy | Image Credit: Gorodenkoff - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
hematological cancer/Image Credit: © nikola-master - stock.adobe.com
breast cancer treatment/Image Credit: © Siam - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.